Last reviewed · How we verify

entecavir, lamivudine — Competitive Intelligence Brief

entecavir, lamivudine (entecavir, lamivudine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Nucleoside reverse transcriptase inhibitor (NRTI). Area: Virology / Hepatology.

marketed Nucleoside reverse transcriptase inhibitor (NRTI) Hepatitis B virus reverse transcriptase Virology / Hepatology Small molecule Live · refreshed every 30 min

Target snapshot

entecavir, lamivudine (entecavir, lamivudine) — Asan Medical Center. Entecavir and lamivudine are nucleoside reverse transcriptase inhibitors that block hepatitis B virus replication by inhibiting the viral reverse transcriptase enzyme.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
entecavir, lamivudine TARGET entecavir, lamivudine Asan Medical Center marketed Nucleoside reverse transcriptase inhibitor (NRTI) Hepatitis B virus reverse transcriptase
Blank maleate entecavir tablets Blank maleate entecavir tablets Chia Tai Tianqing Pharmaceutical Group Co., Ltd. marketed Nucleoside reverse transcriptase inhibitor Hepatitis B virus reverse transcriptase
entecavir (BARACLUDE®) entecavir (BARACLUDE®) National Taiwan University Hospital marketed Nucleoside reverse transcriptase inhibitor (NRTI) Hepatitis B virus reverse transcriptase / HBV polymerase
Placebo & Entecavir Placebo & Entecavir Fu-Sheng Wang marketed Nucleoside reverse transcriptase inhibitor (NRTI) Hepatitis B virus reverse transcriptase / HBV polymerase
Telbivudine (Standard of Care) Telbivudine (Standard of Care) Nanfang Hospital, Southern Medical University marketed Nucleoside reverse transcriptase inhibitor (NRTI) Hepatitis B virus reverse transcriptase
Adefovir dipivoxil (adefovir) Adefovir dipivoxil (adefovir) Merck Sharp & Dohme LLC marketed Nucleotide reverse transcriptase inhibitor Hepatitis B virus reverse transcriptase / DNA polymerase
Hepsera and lamivudine Hepsera and lamivudine University of Washington marketed Nucleoside/nucleotide reverse transcriptase inhibitor Hepatitis B virus reverse transcriptase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Nucleoside reverse transcriptase inhibitor (NRTI) class)

  1. French National Agency for Research on AIDS and Viral Hepatitis · 3 drugs in this class
  2. Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · 2 drugs in this class
  3. ViiV Healthcare · 2 drugs in this class
  4. Nanfang Hospital, Southern Medical University · 2 drugs in this class
  5. Asan Medical Center · 1 drug in this class
  6. Dong-A ST Co., Ltd. · 1 drug in this class
  7. Bristol-Myers Squibb · 1 drug in this class
  8. Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) · 1 drug in this class
  9. Fu-Sheng Wang · 1 drug in this class
  10. Avexa · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). entecavir, lamivudine — Competitive Intelligence Brief. https://druglandscape.com/ci/entecavir-lamivudine. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: